These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27374158)

  • 1. Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease.
    Tartaglione AM; Armida M; Potenza RL; Pezzola A; Popoli P; Calamandrei G
    Behav Brain Res; 2016 Oct; 313():53-57. PubMed ID: 27374158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Popoli P; Pezzola A; Reggio R; Calamandrei G
    Behav Brain Res; 2004 Jul; 152(2):375-83. PubMed ID: 15196806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
    Haik KL; Shear DA; Schroeder U; Sabel BA; Dunbar GL
    Exp Neurol; 2000 Jun; 163(2):430-9. PubMed ID: 10833318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input.
    Schwarz M; Block F; Töpper R; Sontag KH; Noth J
    Ann Neurol; 1992 Sep; 32(3):358-64. PubMed ID: 1329611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid].
    Francis L; Cruz R; Antúnez I; Rosillo JC
    Rev Neurol; 2000 Jun 1-15; 30(11):1016-21. PubMed ID: 10904945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.
    Borlongan CV; Randall TS; Cahill DW; Sanberg PR
    Brain Res; 1995 Apr; 676(1):231-4. PubMed ID: 7796175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual evoked potentials in the rat quinolinic acid model of Huntington's disease.
    Schwarz M; Block F
    Neurosci Lett; 1993 Apr; 152(1-2):81-3. PubMed ID: 8390629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala
    Verma MK; Goel R; Nandakumar K; Nemmani KVS
    Eur J Pharmacol; 2018 Jun; 828():31-41. PubMed ID: 29577894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal characterization of cognitive and motor deficits in an excitotoxic lesion model of striatal dysfunction in non-human primates.
    Lavisse S; Williams S; Lecourtois S; van Camp N; Guillermier M; Gipchtein P; Jan C; Goutal S; Eymin L; Valette J; Delzescaux T; Perrier AL; Hantraye P; Aron Badin R
    Neurobiol Dis; 2019 Oct; 130():104484. PubMed ID: 31132407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.
    Emerich DF; Mooney DJ; Storrie H; Babu RS; Kordower JH
    Neurotox Res; 2010 Jan; 17(1):66-74. PubMed ID: 19588214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis.
    Schackel S; Pauly MC; Piroth T; Nikkhah G; Döbrössy MD
    Behav Brain Res; 2013 Nov; 256():56-63. PubMed ID: 23916743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease.
    Joel D; Ayalon L; Tarrasch R; Weiner I
    Mov Disord; 2003 Dec; 18(12):1499-507. PubMed ID: 14673887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural progenitor implantation restores metabolic deficits in the brain following striatal quinolinic acid lesion.
    Visnyei K; Tatsukawa KJ; Erickson RI; Simonian S; Oknaian N; Carmichael ST; Kornblum HI
    Exp Neurol; 2006 Feb; 197(2):465-74. PubMed ID: 16310773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
    Olds ME; Jacques DB; Kopyov O
    Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
    Ryu JK; Kim SU; McLarnon JG
    Exp Neurol; 2003 Oct; 183(2):700-4. PubMed ID: 14552912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.